Overweight & Obesity

Diets compared for mild-to-moderate crohn disease in adults

(HealthDay)—The specific carbohydrate diet (SCD) is not superior to the Mediterranean diet (MD) for the remission of symptoms in adults with mild-to-moderate Crohn disease (CD), according to a study published online May 26 in Gastroenterology.

James D. Lewis, M.D., from the University of Pennsylvania in Philadelphia, and colleagues randomly assigned 194 adult patients with CD and mild-moderate symptoms to either MD or SCD for 12 weeks.

The researchers found that the percentage of participants who achieved symptomatic remission at week 6 was not superior with SCD (SCD: 46.5 percent; MD: 43.5 percent). Eight of 23 SCD participants and four of 13 MD participants achieved fecal calprotectin (FC) response (50 percent among those with baseline FC >250 μg/g), while two of 37 and one of 28, respectively, achieved a C-reactive protein (CRP) response (high-sensitivity CRP 50 percent reduction from baseline among those with high-sensitivity CRP >5 mg/L).

“Given these results, the greater ease of following the MD, and other health benefits associated with MD, the MD may be preferred to the SCD for most patients with CD with mild-to-moderate symptoms,” the authors write.

Several authors disclosed financial ties to the pharmaceutical and biopharmaceutical industries.


What diet is most likely to help ease Crohn’s disease?


More information:
Abstract/Full Text (subscription or payment may be required)

Copyright © 2021 HealthDay. All rights reserved.

Citation:
Diets compared for mild-to-moderate crohn disease in adults (2021, June 9)
retrieved 9 June 2021
from https://medicalxpress.com/news/2021-06-diets-mild-to-moderate-crohn-disease-adults.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button

Ad Block Detected

Welcome to Mediexpose, Please support our journalism by allowing ads. With support from readers like you, we can continue to deliver the best. You can support us free by simply allowing ads.